CSE : ENBI | OTCQB : ENTBF

In a Unique Position to Challenge the Narrative Around Addiction Recovery

Leveraging emerging biotechnology, Entheon Biomedical Corp. is pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of substance use disorder. Focusing primarily on the powerful DMT molecule, Entheon exists to invert the addiction recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.

This form collects information we will use to send you information on market news and insightful information for your portfolio. We will not share or sell your personal information. You can unsubscribe at any time.

Development
Developing a comprehensive psychedelic medicine platform that incorporates technology and the ideal psychedelic molecule for the treatment of addiction

Platform
Entheon IQ is a fully integrated psychedelic medicine platform that utilizes genetics and EEG biomarkers to personalize assessment, monitoring, and therapy design, replacing uncertainty and subjectivity with data and empiricism

Production
Conducting clinical trials with DMT which is a highly potent and short-acting psychedelic molecule. This flexibility allows for greater control, safety and personalization of program design

Learn more about this

New Dimension in Addiction Treatment

REQUEST
INVESTOR INFO